Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
WILMINGTON, Del., Nov. 28, 2016 -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Synutra International, Inc. (“Synutra” or the “Company”) relating to the sale of the Company to Beams Power Investment Limited (“Beams Power”), an entity affiliated Liang Zhang, Synutra’s chairman, chief executive officer and holder of 63% of Synutra’s outstanding shares. On November 17, 2016, the two parties announced the signing of a definitive merger agreement pursuant to which Beams Power will acquire Synutra in a going private merger. As a result of the merger, Synutra shareholders are only anticipated to receive $6.05 per share in cash in exchange for each share of Synutra.
Andrews & Springer’s investigation so far has revealed that the consideration Synutra shareholders are expected to receive is inadequate. While the Company claims that shareholders will receive a premium for their shares, the deal consideration is significantly less than the $6.74 price target set by an analyst on Yahoo Finance! The current $6.05 per share consideration being offered by Mr. Zhang is currently more than 10% below that target. Our investigation has also revealed that the process leading up to the announcement of the merger appears to have significant conflicts of interest thus making the process and consideration unfair.
If you own shares of Synutra and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/synutra-class-action-investigation/ or contact Craig J. Springer, Esq. at [email protected], or call toll free at 1-800-423-6013. You may also follow us on LinkedIn – www.linkedin.com/company/andrews-&-springer-llc, Twitter – www.twitter.com/AndrewsSpringer or Facebook - www.facebook.com/AndrewsSpringer for future updates.
Andrews & Springer is a boutique securities class action law firm representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty or corporate misconduct. Having formerly defended some of the largest financial institutions in the world, our founding members use their valuable knowledge, experience, and superior skill for the sole purpose of achieving positive results for investors. These traits are the hallmarks of our innovative approach to each case our Firm decides to prosecute. For more information please visit our website at www.andrewsspringer.com. This notice may constitute Attorney Advertising.
Contact: Craig J. Springer, Esq. [email protected] Toll Free: 1-800-423-6013
